Bookmark This Page | E-mail This Page | Print This Page

Investigational Research

Oncology research has been a priority at AstraZeneca since the 1960s. Since that time, we have evaluated numerous drugs for the treatment of a range of cancers and we continue to do so today. Currently, we are investigating several different signaling pathways to evaluate their potential for the treatment of cancer. We invite you to explore these approaches or review our current pipeline.

       
      Phases of development
Research target Mechanism of action Compound Preclinical I II III
             
Anti-angiogenesis and antiproliferation VEGFR, EGFR, and RET tyrosine kinase inhibition Vandetanib
 
 
 
 
             
Anti-angiogenesis VEGF signaling inhibition Cediranib
 
 
 
 
             
Endothelin A receptor antagonist Specific endothelin A receptor inhibition Zibotentan
(ZD4054)
 
 
 
 
             
Antiproliferation MEK 1/2 inhibition AZD6244
(ARRY-
142886)
 
 
 
 
             
             
Inhibition of DNA repair PARP inhibition Olaparib
(AZD2281*)
 
 
 
 
             
Antiproliferation Aurora kinase inhibition AZD1152
 
 
 
   
             
Inhibition of DNA repair Chk1 inhibition AZD7762
 
 
   
             
Antiproliferation and promotion of cell death Inhibition of erbB1, erbB2, and erbB3 receptor signaling AZD8931
 
 
   
             
Antiproliferation mTORC1 and mTORC2 kinase inhibition AZD8055
 
 
   
             
       
Chk1, checkpoint kinase 1; EGFR, epidermal growth factor receptor; MEK, mitogen-activated protein kinase kinase; mTORC, mammalian target of rapamycin complex; PARP, Poly (ADP-ribose) polymerase; RET, rearranged during transfection; VEGFR, vascular endothelial growth factor receptor.
In-licensed from ARRAY BioPharma.
*AZD2281, previously known as KU-0059436, was incorporated into the pipeline following the acquisition of KuDOS Pharmaceuticals Ltd. KuDOS Pharmaceuticals Ltd is a wholly owned subsidiary of AstraZeneca plc.
       
 
 

Next: Investigational Research Slide Kits